Survival outcomes of Stage IB cervical cancer treated with standard radical hysterectomy

Objective: To determine risk factors of survival outcomes in patients with cervical cancer of Stage IB treated with standard hysterectomy (RH). Materials Methods: From February 2001 to November 2015, patients with cervical cancer of FIGO Stage IB were included, if they received RH of Class III or Type C1. Epidemiological and clinic-pathologic characteristics were compared to determine risk factors of overall survival (OS) and progression free survival (PFS). Results: Among 406 patients included, 371 (91.4%) had definite survival data, with recurrence rate and mortality of 17.2% and 9.4%. After a median follow-up of 48.5 (range 12-189) months, and ten-year PFS were 80% and 73%, and five- and ten-year OS were 88% and 84%, respectively. In multivariate analysis, patients with Stage IB2 (HR 2.0, 95% CI 1.2-3.2), positive vaginal margin (HR 9.2, 95% CI 2.6-33.0), or lymphatic metastasis (HR 2.0, 95% CI 1.1-3.6) had higher recurrence; patients with RH before year of 2011 (HR 2.8, 95% 1.3-6.0), Stage IB2 (HR 3.6, 95% CI 1.9-6.9) or lymphatic metastasis (HR 3.6, 95% CI 1.8-7.1) had higher mortality. Recurrent sites or post-recurrent treatment plans had no impact on the survival after recurrence. Conclusion: The prognosis of cervical cancer patients treated with RH by experienced physicians is favorable. Pathologic characters and experiences of surgeons are predictive factors of survival outcomes.

Cervical cancer; Radical hysterectomy; Recurrence; Mortality

[1] Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D.: “Global cancer statistics”. CA Cancer J. Clin., 2011, 61, 69.

[2] Chen W., Zheng R., Baade P.D., Zhang S., Zeng H., Bray F., et al.: “Cancer statistics in China, 2015”. CA Cancer J. Clin., 2016, 66, 115.

[3] Nezhat C.R., Burrell M.O., Nezhat F.R., Benigno B.B., Welander C.E.: “Laparoscopic radical hysterectomy with paraaortic and pelvic node dissection”. Am. J. Obstet. Gynecol., 1992, 166, 864.

[4] Geetha P., Nair M.K.: “Laparoscopic, robotic and open method of radical hysterectomy for cervical cancer: A systematic review“. J. Minim. Access. Surg., 2012, 8, 67.

[5] Piver M.S., Rutledge F., Smith J.P.: “Five classes of extended hysterectomy for women with cervical cancer”. Obstet. Gynecol., 1974, 44, 265.

[6] Cibula D., Abu-Rustum N.R., Benedetti-Panici P., Kohler C., Raspagliesi F., Querleu D., et al.: “New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection”. Gynecol. Oncol., 2011, 122, 264.

[7] Querleu D., Morrow C.P.: “Classification of radical hysterectomy”. Lancet Oncol., 2008, 9, 297.

[8] “Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Available at: http://evs.nci.nih.gov/ftp1/CTCAE/

[9] Howlader N, Noone AM, Krapcho M, Neyman N., Aminou R., Waldron W., et al.: “SEER Cancer Statistics Review, 1975-2012”. National Cancer Institute. Bethesda, MD”. Available at: www.seer. cancer. gov

[10] Sedlis A., Bundy B.N., Rotman M.Z., Lentz S.S., Muderspach L.I., Zaino R.J.: “A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study”. Gynecol. Oncol., 1999, 73, 177.

[11] Ryu S.Y., Park S.I., Nam B.H., Cho C.K., Kim K., Kim B.J., et al.: “Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors?”. Int. J. Radiat. Oncol. Biol. Phys., 2011, 79, 794.

[12] atsuo K., Mabuchi S., Okazawa M., Kawano M., Kuroda H., Kamiura S., et al.: “Clinical implication of surgically treated earlystage cervical cancer with multiple high-risk factors”. J. Gynecol. Oncol., 2015, 26, 3.

[13] Peters W.A., 3rd, Liu P.Y., Barrett R.J., 2nd, Stock R.J., Monk B.J., Berek J.S., et al.: “Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix”. J. Clin. Oncol., 2000, 18, 1606.

[14] Fagundes H., Perez C.A., Grigsby P.W., Lockett M.A.: “Distant metastases after irradiation alone in carcinoma of the uterine cervix”. Int. J. Radiat. Oncol. Biol. Phys., 1992, 24, 197.

[15] Delgado G., Bundy B., Zaino R., Sevin B.U., Creasman W.T., Major F.: “Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1990, 38, 352.

[16] Wright J.D., Lewin S.N., Deutsch I., Burke W.M., Sun X., Herzog T.J.: “The influence of surgical volume on morbidity and mortality of radical hysterectomy for cervical cancer”. Am. J. Obstet. Gynecol., 2011, 205, 225.e221.

[17] Chou H.H., Wang C.C., Lai C.H., Hong J.H., Ng K.K., Chang T.C., et al.: “Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma”. Int. J. Radiat. Oncol. Biol. Phys., 2001, 51, 442.

[18] Jeon W., Koh H.K., Kim H.J., Wu H.G., Kim J.H., Chung H.H.: “Salvage radiotherapy for lymph node recurrence after radical surgery in cervical cancer”. J. Gynecol. Oncol., 2012, 23, 168.

[19] Tempfer C.B., Beckmann M.W.: “State-of-the-Art Treatment and Novel Agents in Local and Distant Recurrences of Cervical Cancer”. Oncol. Res. Treat., 2016, 39, 525.